Recurrent Urinary Tract Infections (rUTI)
Symptoms, Causes, and Prevention
Symptoms, Causes, and Prevention
Symptomatic, recurrent lower urinary tract infections (rUTI) in women are a common condition for which best practice guidelines related to treatment and prevention have not been well established. rUTI affects women of all ages and is defined as 2 or more symptomatic episodes in 6 months or 3 episodes in 1 year. Between 20% to 30% of women who have one UTI will have a rUTI, and approximately 25% of these women will have more recurrent episodes.
Symptoms of rUTI may typically include burning with urination, foul-smelling urine, urinary urgency, and frequency. Treatment strategies should focus on relieving symptoms while at the same time preventing the overuse of antibiotics, which can cause increased side effects as well as the development of antibiotic resistance.
A urine culture before treatment with antibiotics is important to document infection and help determine optimal antibiotic treatment. More complex cases may require renal imaging or cystoscopy.
Short-course treatment of 3-5 days is recommended. Preferred first-line antibiotics are Nitrofurantoin, Trimethoprim-Sulfamethoxazole, and Fosfomycin. Fluoroquinolones such as Cipro are discouraged.
Some prevention strategies include lifestyle and behavioral modifications:
While commonly used to prevent rUTI, there is little data to support the use of Cranberry products or D-mannose. The value of oral and vaginal probiotics is questionable.
Vaginal estrogen therapy reduces vaginal PH, reduces bacterial colonization, restores lactobacillus, and reduces rUTI in postmenopausal women. There is no documentation of increased breast cancer risk or rise in serum Estrogen levels. Oral estrogens do not reduce UTI risk.
This is a bacteriostatic agent that increases urinary levels of formaldehyde. It does not promote antibiotic resistance. There is some evidence that using methenamine as prophylaxis may help prevent rUTI and reduce need for prophylactic antibiotics.
OM-89 (Uro-Vaxom) is an oral vaccine only available in Europe. It appears to be safe and effective in reducing rUTI. Hopefully, this will be available in the U.S. soon
rUTIs are frustrating for women and can significantly impact the quality of life and daily activities. Identifying underlying risk factors is important. There are potentially preventive measures worth discussing with your doctor.
If you have any more questions about the treatment and prevention of rUTIs in women, schedule an appointment with a Georgia Urology expert today.